Baker Bros. Advisors LP Krystal Biotech, Inc. Transaction History
Baker Bros. Advisors LP
- $7.52 Billion
- Q2 2024
A detailed history of Baker Bros. Advisors LP transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 169,934 shares of KRYS stock, worth $31.3 Million. This represents 0.41% of its overall portfolio holdings.
Number of Shares
169,934
Previous 169,934
-0.0%
Holding current value
$31.3 Million
Previous $30.2 Million
3.21%
% of portfolio
0.41%
Previous 0.38%
Shares
14 transactions
Others Institutions Holding KRYS
# of Institutions
266Shares Held
25MCall Options Held
270KPut Options Held
172K-
Black Rock Inc. New York, NY3.95MShares$727 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.87MShares$528 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.43MShares$448 Million6.1% of portfolio
-
State Street Corp Boston, MA1.33MShares$245 Million0.01% of portfolio
-
Redmile Group, LLC San Francisco, CA1.02MShares$188 Million12.22% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $4.73B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...